# EDGAR Filing Document

**Accession Number:** 0001855644
**File Stem:** 0001193125-26-085894
**Filing Date:** 2026-3
**Character Count:** 18626
**Document Hash:** 8a36d5911b85d7f55c0b1f823512dbfe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-085894.hdr.sgml**: 20260302

**ACCESSION NUMBER**: 0001193125-26-085894

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260302

**DATE AS OF CHANGE**: 20260302

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zura Bio Ltd
- **CENTRAL INDEX KEY:** 0001855644
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92696
- **FILM NUMBER:** 26709874

**BUSINESS ADDRESS:**
- **STREET 1:** 4225 EXECUTIVE SQUARE
- **STREET 2:** SUITE 600
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** 858-247-0520

**MAIL ADDRESS:**
- **STREET 1:** 4225 EXECUTIVE SQUARE
- **STREET 2:** SUITE 600
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JATT Acquisition Corp
- **DATE OF NAME CHANGE:** 20210407
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AI Biotechnology LLC
- **CENTRAL INDEX KEY:** 0001942670

**ORGANIZATION NAME:**
- **EIN:** 842172770
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ACCESS INDUSTRIES, INC.
- **STREET 2:** 40 WEST 57TH STREET, 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-247-6400

**MAIL ADDRESS:**
- **STREET 1:** C/O ACCESS INDUSTRIES, INC.
- **STREET 2:** 40 WEST 57TH STREET, 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_1.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Zura Bio Limited**

*(Name of Issuer)*

**Class A Ordinary Shares, par value $0.0001 per share**

*(Title of Class of Securities)*

**G9TY5A101**

*(CUSIP Number)*

**Alejandro Moreno**<br>c/o Access Industries, Inc.<br>40 West 57th Street, 28th Floor<br>New York NY 10019<br>(212) 247-6400

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/26/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G9TY5A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**AI Biotechnology LLC** | Name of reporting person<br>**AI Biotechnology LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**19699071.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**19699071.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**18.2%** | Percent of class represented by amount in Row (11)<br>**18.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1)    The total number of Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares") of Zura Bio Limited (the "Issuer") reported as beneficially owned includes (i) 6,552,725 Class A Ordinary Shares held directly by AI Biotechnology LLC ("AIB") and (ii) 13,146,346 Class A Ordinary Shares issuable upon the conversion of the Private Placement Warrants (as defined in Item 3 herein) held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined in Item 5 herein).

(2)    The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 94,875,460 Class A Ordinary Shares outstanding, as set forth in the Issuer's Current Report on Form 8-K, filed with the SEC on February 26, 2026 and (ii) 13,146,346 Class A Ordinary Shares issuable upon the exercise of Private Placement Warrants held by AIB.

| **CUSIP No.** | **G9TY5A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Access Industries Holdings LLC** | Name of reporting person<br>**Access Industries Holdings LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**19699071.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**19699071.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**18.2%** | Percent of class represented by amount in Row (11)<br>**18.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1)    The total number of Class A Ordinary Shares of the Issuer reported as beneficially owned includes (i) 6,552,725 Class A Ordinary Shares held directly by AIB and (ii) 13,146,346 Class A Ordinary Shares issuable upon the conversion of the Private Placement Warrants held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker.

(2)    The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 94,875,460 Class A Ordinary Shares outstanding, as set forth in the Issuer's Current Report on Form 8-K, filed with the SEC on February 26, 2026 and (ii) 13,146,346 Class A Ordinary Shares issuable upon the exercise of Private Placement Warrants held by AIB.

| **CUSIP No.** | **G9TY5A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Access Industries Management, LLC** | Name of reporting person<br>**Access Industries Management, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**19699071.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**19699071.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**18.2%** | Percent of class represented by amount in Row (11)<br>**18.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1)    The total number of Class A Ordinary Shares of the Issuer reported as beneficially owned includes (i) 6,552,725 Class A Ordinary Shares held directly by AIB and (ii) 13,146,346 Class A Ordinary Shares issuable upon the conversion of the Private Placement Warrants held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker.

(2)    The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 94,875,460 Class A Ordinary Shares outstanding, as set forth in the Issuer's Current Report on Form 8-K, filed with the SEC on February 26, 2026 and (ii) 13,146,346 Class A Ordinary Shares issuable upon the exercise of Private Placement Warrants held by AIB.

| **CUSIP No.** | **G9TY5A101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Len Blavatnik** | Name of reporting person<br>**Len Blavatnik** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**19699071.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**19699071.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | Aggregate amount beneficially owned by each reporting person<br>**19699071.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**18.2%** | Percent of class represented by amount in Row (11)<br>**18.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1)    The total number of Class A Ordinary Shares of the Issuer reported as beneficially owned includes (i) 6,552,725 Class A Ordinary Shares held directly by AIB and (ii) 13,146,346 Class A Ordinary Shares issuable upon the conversion of the Private Placement Warrants held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker.

(2)    The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 94,875,460 Class A Ordinary Shares outstanding, as set forth in the Issuer's Current Report on Form 8-K, filed with the SEC on February 26, 2026 and (ii) 13,146,346 Class A Ordinary Shares issuable upon the exercise of Private Placement Warrants held by AIB.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Ordinary Shares, par value $0.0001 per share

**(b) Name of Issuer:**
Zura Bio Limited

**(c) Address of Issuer's Principal Executive Offices:**
1489 W. Warm Springs Rd. #110, Henderson, NV, 89014

This Amendment No. 1 to Schedule 13D amends the Schedule 13D previously filed with the SEC by the Reporting Persons on May 28, 2025.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of the Schedule 13D is hereby amended and restated as follows:

The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Class A Ordinary Shares (including but not limited to footnotes to such information) are incorporated herein by reference.

The Private Placement Warrants may not be exercised if the aggregate number of Class A Ordinary Shares beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the Class A Ordinary Shares outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the foregoing beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker"). As of the date of this filing, and pursuant to the Beneficial Ownership Blocker, 3,255,460 Class A Ordinary Shares are issuable at any time or times upon the partial conversion of Private Placement Warrants and 13,146,346 Class A Ordinary Shares are issuable upon the conversion of Private Placement Warrants, if AIB delivered notice to the Issuer to increase the beneficial ownership limitation to 19.99% (such notice not to be effective until the sixty-first day after the date such notice is delivered to the Issuer).

**(b)**
The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Class A Ordinary Shares as to which each of the Reporting Persons has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

6,552,725 Class A Ordinary Shares and Private Placement Warrants exercisable into 13,146,346 Class A Ordinary Shares are held directly by AIB and may be deemed to be beneficially owned by AIM, AIH and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

**(c)**
The information set forth in Item 3 hereof is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** AI Biotechnology LLC

**Signature:** /s/ Alejandro Moreno

**Name/Title:** Alejandro Moreno, Executive Vice President

**Date:** 03/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Access Industries Holdings LLC

**Signature:** /s/ Alejandro Moreno

**Name/Title:** Alejandro Moreno, Executive Vice President

**Date:** 03/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Access Industries Management, LLC

**Signature:** /s/ Alejandro Moreno

**Name/Title:** Alejandro Moreno, Executive Vice President

**Date:** 03/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Len Blavatnik

**Signature:** *

**Name/Title:** Len Blavatnik

**Date:** 03/02/2026